Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Rheumatology International
Literature
1.
Wang X, Lin Z, Wei Q et al (2009) Expression of IL-23 and IL-17 and effect of IL-23 on IL-17 production in ankylosing spondylitis. Rheumatol Int 29:1343–1347CrossRefPubMed
2.
Wendling D (2008) Interleukin 23: a key cytokine in chronic inflammatory disease. Joint Bone Spine 75:517–519CrossRefPubMed
3.
Karaderi T, Harvey D, Farrar C et al (2009) Association between the interleukin 23 receptor and ankylosing spondylitis is confirmed by a new UK case control study and meta-analysis of published series. Rheumatology (Oxford) 48:386–389CrossRef
4.
Wendling D, Cedoz JP, Racadot E, Dumoulin G (2007) Serum IL-17, BMP-7, and bone turnover markers in patients with ankylosing spondylitis. Joint Bone Spine. 74:304–305CrossRefPubMed
5.
Jandus C, Bioley G, Rivals JP et al (2008) Increased numbers of circulating polyfunctional Th17 memory cells in patients with seronegative spondylarthritides. Arthritis Rheum 58:2307–2317CrossRefPubMed
6.
Shen H, Goodall JC, Hill Gaston JS (2009) Frequency and phenotype of peripheral blood Th17 cells in ankylosing spondylitis and rheumatoid arthritis. Arthritis Rheum 60:1647–1656CrossRefPubMed
7.
Wendling D, Cedoz JP, Racadot E (2009) Serum and synovial fluid levels of p40 IL12/23 in spondyloarthropathy patients. Clin Rheumatol 28:187–190CrossRefPubMed
8.
Gottlieb A, Menter A, Mendelsohn A et al (2009) Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet 373:633–640CrossRefPubMed
Metadata
Title
IL-23 and IL-17 in ankylosing spondylitis
Author
Daniel Wendling
Publication date
01-09-2010
Publisher
Springer-Verlag
Published in
Rheumatology International / Issue 11/2010
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-009-1226-7

Other articles of this Issue 11/2010

Rheumatology International 11/2010 Go to the issue

Case Report

Lupus myocarditis: marked improvement in cardiac function after intravenous immunoglobulin therapy

Original Article

Ultrasonographic assessment of clinically diagnosed trigger fingers

Review

Atherosclerosis and endothelial dysfunction in patients with ankylosing spondylitis

Original Article

Systemic, secondary and infectious causes for cerebral vasculitis: clinical experience with 16 new European cases

Letter to the Editor

Acute acalculous cholecystitis in systemic sclerosis

Letter to the Editor

Successful treatment of Candida discitis with 5-flucytosine and fluconazole
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits